Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Conversation logo

When electronic cigarettes (e-cigarettes) first emerged, they became a popular way for people to quit smoking. But in 2019, a mysterious lung condition emerged that primarily affected young people, particularly those who vaped. This left many questioning the safety of e-cigarettes.

The condition was named e-cigarettes or vaping use-associated lung injury – or Evali for short. The average (median) age of people affected by the condition was 24 years. Symptoms included respiratory complaints, such as a cough, shortness of breath and chest pain, as well as stomach problems, fever, chills and weight loss.

We now know that Evali is not caused by regulated, commercial nicotine e-cigarettes. Rather, the condition has been linked to products sold as THC-containing e-liquids. Because THC (the active ingredient in cannabis) is expensive, some sellers were cutting their products with vitamin E acetate to make the e-liquid look like it contained more THC than it did. Although vitamin E acetate is an ingredient in some foods and skincare products, it’s harmful when inhaled.

Read the full article on The Conversation website, written by Jamie Hartmann-Boyce, Associate Professor in Nuffield Department of Primary Care Health Sciences.

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

COVID-19 increased public trust in science, new survey shows

A survey of over 2000 British adults has found that public trust in science, particularly genetics, increased significantly during the pandemic. However, those with extremely negative attitudes towards science tend to have high self-belief in their own understanding despite low textbook knowledge.

Gero Miesenböck awarded 2023 Japan Prize

Congratulations to Professor Gero Miesenböck, Department of Physiology, Anatomy and Genetics (DPAG), who has been awarded the 2023 Japan Prize in the field of Life Sciences, together with Professor Karl Deisseroth, for pioneering work in the field of optogenetics.

Major funding for Oxford will help find new cancer treatments

Cancer Research UK and the National Institute for Health and Care Research are investing over £3 million across the next five years into The University of Oxford’s Experimental Cancer Medicine Centre (ECMC). The investment will enable Oxford to expand its portfolio of precision prevention and early detection cancer trials.

Daniel Freeman to join Department of Experimental Psychology as Professor of Psychology

The Department of Experimental Psychology are delighted to announce that Daniel Freeman has been appointed as their new Professor of Psychology, joining from the Department of Psychiatry.

New study reveals role of lymphatic system in bone healing

It was previously assumed that bones lacked lymphatic vessels, but new research from the MRC Human Immunology Unit at Oxford's MRC Weatherall Institute for Molecular Medicine not only locates them within bone tissue, but demonstrates their role in bone and blood cell regeneration and reveals changes associated with aging.

Vaccination shown to protect against pregnancy complications from COVID-19 Omicron variant

The global network led by the Oxford Maternal and Perinatal Health Institute (OMPHI) at the University of Oxford has today published, in The Lancet, the results of the ‘2022 INTERCOVID Study’ conducted in 41 hospitals across 18 countries.